Business Wire

LabVantage Named Global LIMS Company of the Year by Frost & Sullivan

12.9.2024 13:30:00 CEST | Business Wire | Press release

Share

—Company Also Recognized as Growth and Innovation Leader for the Second Year in a Row in 2024 Frost Radar™ for Global Laboratory Information Management Systems (LIMS) for the Life Sciences Market—

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, today announced it has been awarded the prestigious Company of the Year Award in the Global Laboratory Information Management Systems (LIMS) Industry by Frost & Sullivan. This recognition highlights LabVantage’s leadership in visionary innovation, performance, and customer impact, affirming the company’s commitment to delivering cutting-edge, customer-centric solutions across industries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912829381/en/

(Graphic: Business Wire)

The award, part of Frost & Sullivan’s Best Practices Awards series, acknowledges companies that demonstrate excellence in growth and innovation. LabVantage has been recognized for excelling in both dimensions, leveraging its visionary approach to address unmet needs in laboratory informatics while maintaining a strong focus on customer satisfaction and service experience. Over nearly four decades, the company has evolved from a specialized LIMS provider into a vertical Software-as-a-Service (SaaS) platform provider for all laboratory-related digital needs of various industries, including pharmaceuticals, biotechnology, food and beverage, oil and gas, contract testing, public health labs, forensics, and government.

“LabVantage distinguishes itself with an extensive product lineup, smooth integration capabilities, and dedication to facilitating digital transformation in laboratories,” said Lucila Martin, Healthcare & Life Sciences Research Analyst at Frost & Sullivan. “Given the early and strategic growth of SaaS as part of its business, the company enhances its ability to capitalize on LIMS market trends and opportunities.”

Additionally, LabVantage has been named a leader, for the second consecutive year, in the 2024 Frost Radar™ for Global LIMS for the life sciences industry – providing yet another testament to its continued leadership and adaptability in a rapidly evolving sector. In the Radar, Frost & Sullivan evaluated 50 LIMS vendors, plotting the top 14 for their advanced capabilities in interoperability, scalability, and configurability. Companies on the Radar adopt a robust vision focused on growth and rigorous innovation that promotes seamless integration of new technologies, identifies the critical needs of each area, and offers distinctive features for each use of their solutions. A leading player in this Radar analysis, LabVantage scored a high 4.6 on the Innovation index, and similarly, a 4.5 on the Growth index.

“It is a great honor to be awarded Company of the Year in the Global LIMS industry by an esteemed industry advisory firm such as Frost & Sullivan,” said Mikael Hagstroem, CEO of LabVantage Solutions. “This recognition is a result of the dedication and passion that my 1223 colleagues put into changing from a product-centric to a truly client-focused company with a focus on delivering client impact. Earning the Frost Radar recognition two years in a row is a humbling and rare feat for any company – for us, it underscores how closely we partner with our customers to drive innovation. We are proud that our efforts to listen to and innovate based on customer feedback are being recognized, validating our commitment to delivering impact and partnering with our clients for the betterment of the human condition.”

Customers benefit from LabVantage’s robust SaaS offerings, which enable continuous innovation, operational efficiency, and reduced capital expenditures. The company’s internal professional services team, which manages significant implementation work in-house, also plays a critical role in delivering impact that is consistently growing over time. For example, they help clients by shortening time for validation and providing services, such as instrument integration, master data management, and generative artificial intelligence (AI)-based augmentation. In April 2024, LabVantage achieved over 100 software deployments for fiscal year 2024 across the various industries it serves.

LabVantage continues to expand its global footprint, with strategic growth initiatives in Colombia, Brazil, South Korea, and Hong Kong, and has enhanced its capabilities through acquisitions, such as SEIN Infotech. The company’s investment in emerging technologies, including generative AI, is further solidifying its leadership in laboratory informatics, offering customers more intelligent and efficient systems.

For more information on LabVantage and its comprehensive LIMS solutions, visit www.labvantage.com or email info@labvantage.com.

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise or via SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912829381/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye